SUPN News and Press, Supernus Pharmaceuticals Inc. From 02/28/21

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2020 Earnings Conference Call February 25, 2021, 16:30 ET Company Participants Peter Vozzo - Westwicke Partners Jack Khattar - Founder, President, CEO, Secretary & Director James Kelly - EVP & CFO Conference Call Participants David Steinberg - ...

Image source: The Motley Fool. Supernus Pharmaceuticals Inc (NASDAQ: SUPN) Q4 2020 Earnings Call Feb 25, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Supernus Pharmaceuticals Inc (SUPN) Q4 2020 Earnings Call Tran...

ROCKVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of Su...

Supernus Pharmaceuticals (SUPN): Q4 GAAP EPS of $0.57.Revenue of $143.56M (+42.9% Y/Y)Press Release For further details see: Supernus Pharmaceuticals reports Q4 results

Full year 2020 total revenues of $520.4 million, a 32% increase compared to 2019 Full year 2020 operating earnings of $173.7 million, a 17% increase compared to 2019 SPN-812 NDA assigned an early April 2021 PDUFA date Positive results from Phase III study for SPN-812 in adults...

ROCKVILLE, Md., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report busi...

ROCKVILLE, Md., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it received notice from the U.S. F...

Following a ~4.4% gain yesterday, Supernus Pharmaceuticals ([[SUPN]] +2.1%) is back in the positive territory today after it announced the resubmission of the New Drug Application (“NDA”) for SPN-812 in the treatment of ADHD in pediatric patients.In November, the company&#x...

ROCKVILLE, Md., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced it has resubmitted its New Drug Applica...

ROCKVILLE, Md., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company's management will present...